Literature DB >> 3365670

Essential thrombocythemia. Clinical characteristics and course of 61 cases.

R Hehlmann1, M Jahn, B Baumann, W Köpcke.   

Abstract

Sixty-one patients with essential thrombocythemia (ET) were followed from 1974 through 1987 at the Medizinische Poliklinik. Fifty-one patients (84%) presented with thromboembolic complications, and eight patients (13%) with hemorrhages. In seven patients (12%), a thrombocytosis was detected accidentally. Disturbances of the microcirculation (67%), mainly of the fingers and toes (53%), were the most frequent thromboembolic symptoms. The mean age of all patients was 58 years (male patients, 61 years; female patients, 56 years). The average platelet count at diagnosis was 897,000/microliter. The average maximal platelet count was 1.231 X 10(6)/microliter (range, 500,000/microliter to 4 X 10(6)/microliter). Seventy-two percent had a moderate leukocytosis (average, 12,400/microliter), 34% a splenomegaly, 29% a hepatomegaly. Signs of hypermetabolism were infrequent, lactate dehydrogenase (LDH) and uric acid elevations, if present, were moderate. Bleeding time and viscosity were normal in most patients. Spontaneous platelet aggregation was increased in 81% of patients (n = 40). Platelet aggregation studies with the aggregation inducing substances adenosine diphosphonate (ADP), platelet activating factor (PAF), thrombin, collagen, and adrenalin showed hypoaggregation in most patients. Adrenalin-induced aggregation distinguished best between ET-patients and reactive thrombocytosis showing hypoaggregation in all ET-patients tested (n = 16) and in none of 22 controls. Bone marrow studies were performed in 57 patients. The histologic studies (done in 49 patients) were consistent with a chronic myeloproliferative disorder in all cases. In 41 cases (84%) the picture of a megakaryocytic myelosis was found, in 12 of these a granulocyte-rich form of megakaryocytic myelosis. Cytologic studies only (eight patients) did not differentiate ET well from reactive thrombocytosis. Platelet aggregation studies and bone marrow histology may be of help in the diagnosis of difficult cases of thrombocytosis. The Philadelphia status was negative in all cases studied (14 patients). Fourteen patients died. The causes of death were thromboembolic complications in probably 11 and acute leukemia in two patients. The probability of 10-year survival is 64% after a mean follow-up time of approximately 5 years. It appears that considering the average age of ET patients at diagnosis, life expectancy is close to normal.

Entities:  

Mesh:

Year:  1988        PMID: 3365670     DOI: 10.1002/1097-0142(19880615)61:12<2487::aid-cncr2820611217>3.0.co;2-t

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  23 in total

1.  Histologic findings in bone marrow biopsies of patients with thrombocythemic cell counts.

Authors:  T Buhr; A Georgii; O Schuppan; A Amor; V Kaloutsi
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

Review 2.  Common emergencies in cancer medicine: hematologic and gastrointestinal syndromes.

Authors:  C R Thomas; I K Carter; W T Leslie; F Sutton
Journal:  J Natl Med Assoc       Date:  1992-02       Impact factor: 1.798

3.  [Clinical characterization of essential thrombocythemia in comparison to other myeloproliferative diseases and reactive thrombocytoses].

Authors:  R Zankovich; V Diehl
Journal:  Klin Wochenschr       Date:  1988-08-01

4.  Familial essential thrombocythemia: clinical characteristics of 11 cases in one family.

Authors:  R J Schlemper; A P van der Maas; J C Eikenboom
Journal:  Ann Hematol       Date:  1994-03       Impact factor: 3.673

Review 5.  Primary thrombocythemia: diagnosis, clinical manifestations and management.

Authors:  P J van Genderen; J J Michiels
Journal:  Ann Hematol       Date:  1993-08       Impact factor: 3.673

6.  Cardiac surgery in a patient with essential thrombocythemia: a case report.

Authors:  B E Schölzel; H Endeman; W Dewilde; A Yilmaz; O de Weerdt; J M Ten Berg
Journal:  Neth Heart J       Date:  2010-08       Impact factor: 2.380

Review 7.  Hemostatic changes in patients with malignancy.

Authors:  G H Goldsmith
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

Review 8.  What is the standard treatment in essential thrombocythemia.

Authors:  Tiziano Barbui
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

9.  Platelet count and the risk for thrombosis and death in the elderly.

Authors:  J G van der Bom; S R Heckbert; T Lumley; C E Holmes; M Cushman; A R Folsom; F R Rosendaal; B M Psaty
Journal:  J Thromb Haemost       Date:  2008-12-20       Impact factor: 5.824

10.  Essential thrombocythaemia: a single institution experience of 16 years.

Authors:  Sunny Joseph Varghese; Mohamed Bahey El Din; Mona Al Hendi; Ramesh Kumar
Journal:  Indian J Hematol Blood Transfus       Date:  2012-06-26       Impact factor: 0.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.